Advertisement

Lack of H3K27 trimethylation is associated with 1p/19q codeletion in diffuse gliomas

  • Katharina Filipski
  • Yannick Braun
  • Jenny Zinke
  • Bastian Roller
  • Peter Baumgarten
  • Marlies Wagner
  • Christian Senft
  • Pia S. Zeiner
  • Michael W. Ronellenfitsch
  • Joachim P. Steinbach
  • Karl H. Plate
  • Gilles Gasparoni
  • Michel Mittelbronn
  • David Capper
  • Patrick N. HarterEmail author
Open Access
Correspondence

The current World Health Organisation (WHO) Classification of Central Nervous System Tumours defines oligodendrogliomas by IDH mutation and 1p/19q codeletion [12]. Oligodendrogliomas differ from diffuse astrocytomas regarding genetic alterations in telomere maintenance mechanisms by frequently displaying TERT promoter mutations while astrocytomas typically exhibit ATRX (a-thalassaemia/mental retardation syndrome X-linked) mutations leading to alternative lengthening of telomeres (ALT) [1, 2, 7, 10, 13]. The distinction between both glioma types is crucial since it has a considerable impact on both patient treatment and outcome.

Currently, methodological guidelines for the assessment of 1p/19q codeletion are missing and commonly PCR-based loss of heterozygosity analyses or fluorescent in situ hybridization (FISH) are used. IDH mutant astrocytomas and oligodendrogliomas can also be distinguished by DNA methylation-based profiling, which allows 1p/19q assessment via calculated copy number profiles (CNP) [4]. Infinium 850 k EPIC array is a highly reliable and accurate technique for DNA methylation analysis but can currently only be performed by specialized laboratories as it requires substantial investment in infrastructure and personnel.

Trimethylation at lysine 27 of histone 3 (H3K27me3) is a repressive histone mark associated with inhibition of transcription and represents a post-translational modification set by EZH2, a component of the Polycomb repressive complex 2 [5, 15, 16]. In a paediatric ependymoma cohort, reduction of H3K27me3 defines a subgroup of posterior fossa ependymomas with poor prognosis [3, 17]. Likewise, WHO grade I and II meningiomas display a higher risk of recurrence when H3K27me3 is lost [9]. However, since comprehensive data about H3K27me3 in IDH mutant gliomas is missing, we screened an epigenetically well-defined glioma cohort consisting of 26 IDH mutant and 1p/19q codeleted oligodendrogliomas, 34 IDH mutant astrocytomas and 101 IDH wildtype glioblastomas for potential differences in H3K27 trimethylation on protein level.

Diffuse gliomas showed differences in H3K27me3 staining by either displaying nuclear retention or lack of H3K27me3 immunoreactivity (Fig. 1a). In line with H3K27me3 functioning as a transcriptional silencing mechanism via chromatin remodelling for X-inactivation, we also noticed nuclear lack of H3K27me3 in combination with preserved dot-like staining of the inactivated X chromosome in a subgroup of female glioma patients (Fig. 1a). Furthermore, H3K27me3 turned out to be an indicator of patient survival: patients with lack of H3K27me3 expression showed a significantly better prognosis than patients with retained H3K27me3 staining (Supplementary Fig. 1).
Fig. 1

a Immunohistochemistry against H3K27me3. Arrowheads pointing at retained nuclear staining in endothelial cells while tumour cells show a lack of staining (IDH mutant and 1p/19q codeleted oligodendroglioma, left panel). Arrowheads pointing at dot-like H3K27me3 retention in otherwise H3K27me3-negative tumour cells in a case of a female patient (IDH mutant and 1p/19q codeleted oligodendroglioma, middle panel). Nuclear retention of H3K27me3 in a glioblastoma IDH-WT specimen (right panel) (all scale bars 100 µm). b H3K27me3 and c ATRX expression in epigenetically defined glioma subclasses [4] (n.c. non-conclusive). d Decision tree of recursive partitioning using DNA methylation-based classifier diagnosis “IDH mutant and 1p/19q codeleted oligodendroglioma” as dependent variable and H3K27me3, ATRX and IDH1R132H staining as predictors. Decision tree showing results of best split

Next, we set out to compare H3K27me3 immunoreactivity with DNA methylation classes. None of the investigated tumours showed a histone 3 lysine 27 M mutation, as assessed by a mutation-specific antibody (Supplementary Fig. 1). Most interestingly, in IDH mutant and 1p/19q codeleted oligodendroglioma, H3K27me3 retention was never observed, the abundant number of cases (25/26) showed clear lack of nuclear H3K27me3 staining and only one case had to be deemed non-conclusive (Fig. 1b). Gliomas belonging to the DNA methylation class of IDH mutant astrocytomas or IDH mutant high-grade astrocytomas were characterized by nuclear H3K27me3 retention in 69.6% and 81.8%, respectively (Fig. 1b). Malignant gliomas of the DNA methylation class of IDH wildtype glioblastoma predominantly presented with preserved nuclear H3K27me3 staining (86.1%, Fig. 1b). Interestingly, in IDH wildtype glioblastomas, lack of nuclear staining was exclusively associated with methylation subclasses “mesenchymal” (3 out of 36) and “RTK I” (5 out of 26) (Supplementary Fig. 1c displaying examples of H3K27me3 staining in different glioma subtypes). As loss of nuclear ATRX staining and 1p/19q codeletion are mostly mutually exclusive, ATRX immunohistochemistry is useful in discrimination between an oligodendroglial and astrocytic tumour lineage [6, 8, 11, 18]. Nevertheless, non-conclusive ATRX staining impeded diagnosis of oligodendroglioma in 11.5% and might have been misleading in up to 36.4% of IDH mutant high-grade astrocytomas which presented with retained nuclear ATRX staining (Fig. 1c).

To assess the predictive value of H3K27me3 expression in diffuse gliomas we deployed a recursive partitioning model for the prediction of the DNA methylation class IDH mutant and 1p/19q codeleted oligodendroglioma with H3K27me3, ATRX and IDH1R132H staining as predictors (Fig. 1d). Sequential immunohistochemistry against the aforementioned antigens revealed that diffuse gliomas with lack of nuclear H3K27me3 staining, retention or non-conclusive nuclear ATRX staining and IDH1R132H mutation are 1p/19q codeleted oligodendrogliomas with a predicted probability of 0.9678 (Fig. 1d, see also results of a validation cohort in Supplementary Fig. 2).

Our results point to differences in histone H3K27 modification in diffuse glial tumours which are advantageous for the clinically relevant discrimination between astrocytic and oligodendroglial tumour lineage. Results of our prediction model suggests the usage of an antibody panel including antibodies against IDH1R132H, H3K27M (exclusion of mutation), ATRX and H3K27me3 for the prediction of the DNA methylation class “oligodendroglioma, IDH mutant and 1p/19q codeleted” (Supplementary Table 1). In diffuse gliomas harbouring a lack of nuclear H3K27me3 in addition to retained or non-conclusive ATRX staining but no IDH1R132H-mutation, IDH sequencing should be followed up. Small tumour biopsies or infiltration zones require careful evaluation of immunostainings (Supplementary Fig. 1c).

With regard to tumour biology, the lack of nuclear H3K27me3 in oligodendrogliomas is surprising given the fact that increasing levels of 2-hydroxyglutarate in cells harbouring an IDH mutation are known to impair demethylation of other repressive histone marks, such as H3K9me3, with resulting gain of histone methylation [14]. The resulting chromatin compaction would promote CpG island hypermethylation phenotype [19]. The relation between 1p/19q codeletion and global lack of H3K27me3 requires further investigation.

Notes

Acknowledgements

We would like to thank Mrs. Tatjana Starzetz and Mrs. Maika Dunst for excellent technical assistance. MM would like to thank the Luxembourg National Research Fund (FNR) for the support (FNR PEARL P16/BM/11192868 Grant).

Supplementary material

401_2019_2025_MOESM1_ESM.tiff (8.4 mb)
Supplementary Figure 1: (a) Kaplan-Meier survival analyses of a non-molecularly classified tissue micro array (TMA) cohort (1998-2011) of different diffuse gliomas including oligodendrogliomas, astrocytomas, and glioblastomas. (b) Results of IDH1R132H, ATRX, H3K27me3 and H3K27M immunohistochemistry in epigenetically defined glioma subclasses. (c) Collection of H3K27me3 staining patterns in different glioma subtypes (TIFF 8558 kb)
401_2019_2025_MOESM2_ESM.tiff (1.5 mb)
Supplementary Figure 2: Immunohistochemical analyses for IDH1R132H, ATRX, H3K27me3 and H3K27M in the epigenetically classified validation cohort consisting of 18 IDH-mutant gliomas (1p/19q codeleted oligodendrogliomas (n=9); astrocytomas (n=9)) (TIFF 1556 kb)
401_2019_2025_MOESM3_ESM.docx (12 kb)
Supplementary Table 1: Antibodies, supplier and dilution for immunohistochemistry (DOCX 12 kb)

References

  1. 1.
    Abedalthagafi M, Phillips JJ, Kim GE, Mueller S, Haas-Kogen DA, Marshall RE et al (2013) The alternative lengthening of telomere phenotype is significantly associated with loss of ATRX expression in high-grade pediatric and adult astrocytomas: a multi-institutional study of 214 astrocytomas. Mod Pathol.  https://doi.org/10.1038/modpathol.2013.90 Google Scholar
  2. 2.
    Arita H, Narita Y, Fukushima S, Tateishi K, Matsushita Y, Yoshida A et al (2013) Upregulating mutations in the TERT promoter commonly occur in adult malignant gliomas and are strongly associated with total 1p19q loss. Acta Neuropathol 126:267–276.  https://doi.org/10.1007/s00401-013-1141-6 CrossRefGoogle Scholar
  3. 3.
    Bayliss J, Mukherjee P, Lu C, Jain SU, Chung C, Martinez D et al (2016) Lowered H3K27me3 and DNA hypomethylation define poorly prognostic pediatric posterior fossa ependymomas. Sci Transl Med.  https://doi.org/10.1126/scitranslmed.aah6904 Google Scholar
  4. 4.
    Capper D, Jones DTW, Sill M, Hovestadt V, Schrimpf D, Sturm D et al (2018) DNA methylation-based classification of central nervous system tumours. Nature.  https://doi.org/10.1038/nature26000 Google Scholar
  5. 5.
    Czermin B, Melfi R, Mccabe D, Seitz V, Imhof A, Pirrotta V et al (2002) Drosophila enhancer of Zeste/ESC complexes have a histone H3 methyltransferase activity that marks chromosomal polycomb sites. Cell 111:1–12.  https://doi.org/10.1016/S0092-8674(02)00975-3 CrossRefGoogle Scholar
  6. 6.
    Ebrahimi A, Skardelly M, Bonzheim I, Ott I, Mühleisen H, Eckert F et al (2016) ATRX immunostaining predicts IDH and H3F3A status in gliomas. Acta Neuropathol Commun 4:60.  https://doi.org/10.1186/s40478-016-0331-6 CrossRefGoogle Scholar
  7. 7.
    The Cancer Genome Atlas Research Network (2015) Comprehensive, integrative genomic analysis of diffuse lower-grade gliomas. N Engl J Med.  https://doi.org/10.1056/nejmoa1402121 Google Scholar
  8. 8.
    Jiao Y, Killela PJ, Reitman ZJ, Rasheed BA, Heaphy CM, de Wilde RF et al (2012) Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas. Oncotarget.  https://doi.org/10.18632/oncotarget.588 Google Scholar
  9. 9.
    Katz LM, Hielscher T, Liechty B, Silverman J, Zagzag D, Sen R et al (2018) Loss of histone H3K27me3 identifies a subset of meningiomas with increased risk of recurrence. Acta Neuropathol 135:955–963.  https://doi.org/10.1007/s00401-018-1844-9 CrossRefGoogle Scholar
  10. 10.
    Koelsche C, Sahm F, Capper D, Reuss D, Sturm D, Jones DTW et al (2013) Distribution of TERT promoter mutations in pediatric and adult tumors of the nervous system. Acta Neuropathol 126:907–915.  https://doi.org/10.1007/s00401-013-1195-5 CrossRefGoogle Scholar
  11. 11.
    Liu XY, Gerges N, Korshunov A, Sabha N, Khuong-Quang DA, Fontebasso AM et al (2012) Frequent ATRX mutations and loss of expression in adult diffuse astrocytic tumors carrying IDH1/IDH2 and TP53 mutations. Acta Neuropathol 124:615–625.  https://doi.org/10.1007/s00401-012-1031-3 CrossRefGoogle Scholar
  12. 12.
    Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK et al (2016) The 2016 World Health Organization Classification of tumors of the central nervous system: a summary. Acta Neuropathol.  https://doi.org/10.1007/s00401-016-1545-1 Google Scholar
  13. 13.
    Lovejoy CA, Li W, Reisenweber S, Thongthip S, Bruno J, de Lange T et al (2012) Loss of ATRX, genome instability, and an altered DNA damage response are hallmarks of the alternative lengthening of Telomeres pathway. PLoS Genet 8:12–15.  https://doi.org/10.1371/journal.pgen.1002772 CrossRefGoogle Scholar
  14. 14.
    Lu C, Ward PS, Kapoor GS, Rohle D, Turcan S, Abdel-Wahab O et al (2012) IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature 1:1.  https://doi.org/10.1038/nature10860 CrossRefGoogle Scholar
  15. 15.
    Margueron R (2013) The polycomb complex PRC2 and its mark in life. Nature 469:343–349.  https://doi.org/10.1038/nature09784.The CrossRefGoogle Scholar
  16. 16.
    Müller J, Hart CM, Francis NJ, Vargas ML, Sengupta A, Wild B et al (2002) Histone methyltransferase activity of a Drosophila Polycomb group repressor complex. Cell.  https://doi.org/10.1016/s0092-8674(02)00976-5 Google Scholar
  17. 17.
    Panwalkar P, Clark J, Ramaswamy V, Hawes D, Yang F, Dunham C et al (2017) Immunohistochemical analysis of H3K27me3 demonstrates global reduction in group-A childhood posterior fossa ependymoma and is a powerful predictor of outcome. Acta Neuropathol 1:1.  https://doi.org/10.1007/s00401-017-1752-4 Google Scholar
  18. 18.
    Reuss DE, Sahm F, Schrimpf D, Wiestler B, Capper D, Koelsche C et al (2015) ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an “integrated” diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma. Acta Neuropathol 129:133–146.  https://doi.org/10.1007/s00401-014-1370-3 CrossRefGoogle Scholar
  19. 19.
    Turcan S, Rohle D, Goenka A, Walsh LA, Fang F, Yilmaz E et al (2012) IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature.  https://doi.org/10.1038/nature10866 Google Scholar

Copyright information

© The Author(s) 2019

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Authors and Affiliations

  • Katharina Filipski
    • 1
    • 2
    • 3
  • Yannick Braun
    • 1
  • Jenny Zinke
    • 1
  • Bastian Roller
    • 1
  • Peter Baumgarten
    • 1
    • 4
  • Marlies Wagner
    • 5
  • Christian Senft
    • 4
  • Pia S. Zeiner
    • 6
    • 7
  • Michael W. Ronellenfitsch
    • 6
    • 7
    • 8
  • Joachim P. Steinbach
    • 6
    • 7
    • 8
  • Karl H. Plate
    • 1
    • 2
    • 3
    • 8
  • Gilles Gasparoni
    • 9
  • Michel Mittelbronn
    • 10
    • 11
    • 12
    • 13
  • David Capper
    • 14
    • 15
    • 16
  • Patrick N. Harter
    • 1
    • 2
    • 3
    • 8
    Email author
  1. 1.Institute of Neurology, (Edinger Institute)University HospitalFrankfurt Am MainGermany
  2. 2.German Cancer Consortium (DKTK), Partner Site Frankfurt/MainzHeidelbergGermany
  3. 3.German Cancer Research Center (DKFZ)HeidelbergGermany
  4. 4.Department of NeurosurgeryUniversity HospitalFrankfurt Am MainGermany
  5. 5.Institute of NeuroradiologyUniversity HospitalFrankfurt Am MainGermany
  6. 6.Department of NeurologyUniversity HospitalFrankfurt Am MainGermany
  7. 7.Dr. Senckenberg Institute of NeurooncologyUniversity HospitalFrankfurt Am MainGermany
  8. 8.Frankfurt Cancer Institute (FCI)Frankfurt Am MainGermany
  9. 9.Department of GeneticsUniversity of SaarlandSaarbrückenGermany
  10. 10.Luxembourg Centre of Neuropathology (LCNP)Luxembourg CityLuxembourg
  11. 11.Luxembourg Centre for Systems Biomedicine (LCSB)University of LuxembourgLuxembourg CityLuxembourg
  12. 12.Laboratoire National de Santé (LNS)DudelangeLuxembourg
  13. 13.NORLUX Neuro-Oncology LaboratoryLuxembourg Institute of Health (LIH)LuxembourgLuxembourg
  14. 14.Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität BerlinHumboldt-Universität zu BerlinBerlinGermany
  15. 15.Department of NeuropathologyBerlin Institute of HealthBerlinGermany
  16. 16.German Cancer Consortium (DKTK), Partner Site BerlinGerman Cancer Research Center (DKFZ)HeidelbergGermany

Personalised recommendations